¡Activa las notificaciones laborales por email!
A leading cancer research institute in Badalona is seeking a Predoctoral Researcher for its Stem cell biology, developmental leukemia, and immunotherapy group. Candidates should have a Master’s degree in biomedical sciences and experience in cell and molecular biology. The role offers a full-time contract focusing on innovative cancer treatments in a highly collaborative environment.
The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conducting research and driving innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC). Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar, and Hospital San Joan de Déu.
We are looking for a Predoctoral Researcher for the Stem cell biology, developmental leukemia, and immunotherapy group led by Dr. Pablo Menéndez.
Pediatric cancer is relatively uncommon, with approximately 1,200 new cases diagnosed each year in Spain. Progress in these rare tumors still relies almost entirely on academic research, as they are not considered profitable, and contributions from the pharmaceutical industry remain very limited. Our laboratory, in collaboration with researchers and physicians at Hospital Sant Joan de Déu, has developed a CAR T-cell therapy for Ewing sarcoma. The project is now entering a stage where we must characterize the tumor microenvironment and design safety strategies in preparation for potential future clinical implementation.
We are looking for a highly motivated PhD student, with postgraduate studies in biomedicine, immunology, or cell and molecular biology.
Deadline: Please submit your application by October 16th, 2025.
The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.